Argano, a pioneering global consulting firm specializing in the design and delivery of high-performance business operations with an AI-forward approach to transformation, has acquired Pharosity Consulting, Inc.

“As we move into 2026, Argano continues to build momentum through a disciplined acquisition strategy that is expanding both our scale and industry depth,” Chip Register, Group CEO of Plano-based Argano, said in a statement. “Pharosity’s distinct specialization and proven team complement our platform well, and we’re excited to welcome them to Argano. This acquisition supports our continued focus on delivering AI-enabled high-performance operations for pharmaceutical organizations facing increasingly complex regulatory and data environments.”

Aggano had a busy 2025, moving into its new Plano headquarters, complete with basketball court, and acquiring numerous companies. The Pharosity transaction is Argano’s eighth deal since the launch of its transformational growth program in April 2025, and the twenty-fourth since the company’s founding in 2020.

Based in Doylestown, Pennsylvania, Pharosity specializes in Gross-to-Net government pricing, commercial contracting, and advanced analytics for pharmaceutical and biotech companies. Founded in 2015, Pharosity reinforces Argano’s strategy to expand domain-specific capabilities and scale differentiated offerings. The acquisition boosts Argano’s ability to help clients modernize finance, revenue, and analytics operations in highly regulated, data-intensive environments, the company said.

Pharosity provides a structured operating model designed to support complex regulatory and commercial functions with consistency and speed, Argano said. Its strong command of policy-driven processes and tailored delivery methods allow for more resilient revenue operations and scalable compliance programs. With mature methodologies and strong client relationships, Pharosity enhances Argano’s position as a trusted partner for transformation in highly dynamic operating environments, while also providing a management methodology that complements and strengthens Argano’s Strategic Business Consulting capabilities, the company said.

Support for complex regulatory and commercial demands

Pharosity’s services are highly complementary to those of Twelve Consulting Group, which joined Argano in 2025, enhancing the firm’s FP&A, ERP, and analytics solutions across the life sciences value chain. Together, they create a differentiated, end-to-end offering that combines strategic advisory, advanced analytics, and enterprise technology customized for pharmaceutical manufacturers facing evolving regulatory and commercial demands.

For pharmaceutical, medical device, and diagnostic companies, the expanded framework empowers the optimization of core operating models while supporting more comprehensive regulatory engagement and compliance, delivered through Argano’s broader portfolio spanning business applications, AI, cloud infrastructure, data integration, and performance management, the company said.

“Joining Argano enables us to extend our reach while continuing to deliver the focused expertise our clients value,” said Brian Barbash, co-founder of Pharosity. “We’re excited to scale within a platform that prioritizes precision, partnership, and sustainable outcomes, expanding what we can provide to our pharmaceutical clients as they navigate complexities and drive better results” he said.

This transaction closed in December 2025. Bass, Berry & Simms served as legal advisor to Argano. Ernst & Young provided financial diligence advisory. KHSA and Wipfli served as financial advisors and Messerli Kramer as legal advisor to Pharosity.

Don’t miss what’s next. Subscribe to Dallas Innovates.

Track Dallas-Fort Worth’s business and innovation landscape with our curated news in your inbox Tuesday-Thursday.